Vaginal Cancer Clinical Trials

Find Vaginal Cancer Clinical Trials Near You

Methylation Profiling in Self-samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of the MYSSELF study is to investigate which biological markers (i.e., (epi)genetic biomarkers) found in self-collected samples, such as first-void urine and vaginal samples, are linked to the presence of endometrial, ovarian, vulvar, or vaginal (pre-)cancer or to postmenopausal bleeding. Samples collected by clinicians from the cervix or vulva, as well as blood and tissue samples, will be used for comparison. The study will explore whether these markers could help improve earlier and less invasive detection of gynecological cancers in the future.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:

• Individuals having female genital organs, regardless of their gender identity

• 18 years old or older at the time of signing the informed consent form

• Diagnosed with either endometrial, ovarian, vulvar, or vaginal cancer irrespective of stage; diagnosed with one of their precursor lesions; or individuals with postmenopausal bleeding

• Has not started any form of cancer treatment prior to study enrolment

• Written informed consent must be obtained from each participant

• The participant is able to understand the information brochure and what the study is about

Locations
Other Locations
Belgium
University Hospital of Antwerp (UZA)
RECRUITING
Edegem
Contact Information
Primary
Tine Pinxteren, MSc
tine.pinxteren@uantwerpen.be
476014843
Time Frame
Start Date: 2026-06-19
Estimated Completion Date: 2032-12-31
Participants
Target number of participants: 730
Treatments
Experimental: Sample collection
Participants will collect one first-void urine sample and one vaginal self-sample at home, the day before or the day of their planned consultation at the hospital or at the hospital itself. During the hospital visit, an additional clinician-collected cervical and/or vulvar sample and a blood sample will be collected for the study. If a tissue sample is already being taken as part of the participant's standard treatment or diagnostic follow-up, it will also be used for this study. Current diagnostic results (e.g., dilation \& curettage, transvaginal ultrasonography, blood biomarker CA-125, vulvoscopy, echography, imaging (CT, PET, MRI)) and cancer (histology) diagnoses will be used as the final diagnosis.
Sponsors
Collaborators: University Hospital, Antwerp
Leads: Universiteit Antwerpen

This content was sourced from clinicaltrials.gov